Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.
Τίτλος | Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., Papadimitriou C., Kostopoulos I., Koletsa T., Tsolaki E., Televantou D., Timotheadou E., Koutras A., Klouvas G., Samantas E., Pisanidis N., Karanikiotis C., Sfakianaki I., Pavlidis N., Gogas H., Linardou H., Kalogeras K. T., Pectasides D., & Dimopoulos M. A. |
Journal | BMC Cancer |
Volume | 13 |
Pagination | 163 |
Date Published | 2013 Mar 28 |
ISSN | 1471-2407 |
Λέξεις κλειδιά | Adult, Aged, Anthracyclines, Antigens, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Centromere, Chromosome Aberrations, Chromosomes, Human, Pair 17, Clinical Trials, Phase III as Topic, DNA Topoisomerases, Type II, DNA-Binding Proteins, Female, Gene Dosage, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Middle Aged, Neoplasm Grading, Neoplasm Staging, Odds Ratio, Poly-ADP-Ribose Binding Proteins, Prognosis, Randomized Controlled Trials as Topic, Receptor, ErbB-2, Young Adult |
Abstract | BACKGROUND: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has been associated with response to anthracyclines. Limited information exists on the relationship of HER2/TOP2A gene status in the presence of centromere 17 (CEP17) gain with outcome of patients treated with anthracycline-containing adjuvant chemotherapy. |
DOI | 10.1186/1471-2407-13-163 |
Alternate Journal | BMC Cancer |
PubMed ID | 23537287 |
PubMed Central ID | PMC3621498 |